Cyclerion Therapeutics Inc (OQ:CYCN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 301 Binney St
CAMBRIDGE MA 02142-1030
Tel: N/A
Website: N/A
IR: N/A
<
Key People
N/A    
Business Overview
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company's portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.
Financial Overview
For the three months ended 31 March 2019, Cyclerion Therapeutics Inc revenues was not reported. Net loss increased 48% to $37.4M. Higher net loss reflects General & Administrative - Balancing increase from $2.9M to $8.8M (expense), Research & Development - Balancing value increase of 24% to $24.6M (expense), Stock-based Compensation in SGA increase from $843K to $2.2M (expense).
Employees: 140 as of Feb 28, 2019
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Mar 31, 2019
EBITDA (TTM): -$126.02M as of Mar 31, 2019
Net annual income (TTM): -$127.35M as of Mar 31, 2019
Free cash flow (TTM): N/A
Net Debt Last Fiscal Year: $0.00M as of Mar 31, 2019
Shares outstanding: 27,401,660 as of May 8, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization